JP2016501249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501249A5 JP2016501249A5 JP2015545896A JP2015545896A JP2016501249A5 JP 2016501249 A5 JP2016501249 A5 JP 2016501249A5 JP 2015545896 A JP2015545896 A JP 2015545896A JP 2015545896 A JP2015545896 A JP 2015545896A JP 2016501249 A5 JP2016501249 A5 JP 2016501249A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acid
- dha
- dpa
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 83
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 62
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 54
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 54
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 36
- 229930195729 fatty acid Natural products 0.000 claims description 36
- 239000000194 fatty acid Substances 0.000 claims description 36
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 27
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 27
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 27
- 150000004665 fatty acids Chemical group 0.000 claims description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 7
- 125000004494 ethyl ester group Chemical group 0.000 claims description 4
- 235000021588 free fatty acids Nutrition 0.000 claims description 4
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 2
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 2
- 102000018619 Apolipoproteins A Human genes 0.000 claims description 2
- 108010027004 Apolipoproteins A Proteins 0.000 claims description 2
- 102000018616 Apolipoproteins B Human genes 0.000 claims description 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 2
- -1 docosahexaenoic acid (DHA) fatty acids Chemical class 0.000 claims 15
- 239000002253 acid Substances 0.000 claims 8
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 3
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 claims 3
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 241000283080 Proboscidea <mammal> Species 0.000 claims 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 17
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734331P | 2012-12-06 | 2012-12-06 | |
| US61/734,331 | 2012-12-06 | ||
| US201361780948P | 2013-03-13 | 2013-03-13 | |
| US61/780,948 | 2013-03-13 | ||
| PCT/US2013/073714 WO2014089511A2 (en) | 2012-12-06 | 2013-12-06 | Methods of administering compositions comprising docosapentaenoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501249A JP2016501249A (ja) | 2016-01-18 |
| JP2016501249A5 true JP2016501249A5 (enExample) | 2017-01-26 |
Family
ID=50884050
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545896A Pending JP2016501249A (ja) | 2012-12-06 | 2013-12-06 | ドコサペンタエン酸を含む組成物の投与 |
| JP2015545894A Expired - Fee Related JP6881893B2 (ja) | 2012-12-06 | 2013-12-06 | ω３ペンタエン酸組成物および使用方法 |
| JP2019114492A Pending JP2019172697A (ja) | 2012-12-06 | 2019-06-20 | ω３ペンタエン酸組成物および使用方法 |
| JP2021084578A Pending JP2021120407A (ja) | 2012-12-06 | 2021-05-19 | ω３ペンタエン酸組成物および使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545894A Expired - Fee Related JP6881893B2 (ja) | 2012-12-06 | 2013-12-06 | ω３ペンタエン酸組成物および使用方法 |
| JP2019114492A Pending JP2019172697A (ja) | 2012-12-06 | 2019-06-20 | ω３ペンタエン酸組成物および使用方法 |
| JP2021084578A Pending JP2021120407A (ja) | 2012-12-06 | 2021-05-19 | ω３ペンタエン酸組成物および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (3) | EP2928462A4 (enExample) |
| JP (4) | JP2016501249A (enExample) |
| KR (3) | KR20150103671A (enExample) |
| CN (4) | CN112107570A (enExample) |
| AU (7) | AU2013354979A1 (enExample) |
| CA (2) | CA2894366A1 (enExample) |
| IN (2) | IN2015DE05009A (enExample) |
| MX (2) | MX2015007085A (enExample) |
| WO (2) | WO2014089501A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101568665B1 (ko) | 2015-07-21 | 2015-11-12 | 디와이오토 주식회사 | 모터의 맥동 전류를 증가시키는 브러시 구조 |
| EP3475704A1 (en) * | 2016-06-28 | 2019-05-01 | Nestec S.A. | Biomarkers of blood-brain barrier dysfunction |
| JP2018168139A (ja) * | 2016-10-21 | 2018-11-01 | マルハニチロ株式会社 | ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用 |
| JP7099821B2 (ja) * | 2017-12-20 | 2022-07-12 | ポッカサッポロフード＆ビバレッジ株式会社 | Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物 |
| EP3586642A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Ala enriched polyunsaturated fatty acid compositions |
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2002125618A (ja) * | 2000-10-30 | 2002-05-08 | Katsuyuki Wakatsuki | 健康食品 |
| EP1714564A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Method for treatment and prevention of respiratory insufficiency |
| WO2007058523A1 (en) | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
| NZ573719A (en) * | 2006-07-05 | 2011-08-26 | Photonz Corp Ltd | Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis |
| KR100684642B1 (ko) * | 2006-09-14 | 2007-02-22 | 주식회사 일신웰스 | 어유 유래 글리세라이드 유지 조성물 및 이의 제조방법 |
| AU2010222648B2 (en) * | 2009-03-09 | 2016-07-07 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
| US20110071090A1 (en) * | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
| US8241672B2 (en) * | 2009-03-11 | 2012-08-14 | Stable Solutions Llc | Omega-3 enriched fish oil-in-water parenteral nutrition emulsions |
| CN102458109B (zh) * | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| LT2443246T (lt) * | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją |
| WO2012112531A1 (en) * | 2011-02-16 | 2012-08-23 | Pivotal Therapeutics, Inc. | Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases |
| JP2014505729A (ja) * | 2011-02-16 | 2014-03-06 | ピヴォタル セラピューティクス インコーポレイテッド | コレステロールの低減および心血管事象の低減のための、コレステロール吸収阻害剤（アゼチジノン）およびω３脂肪酸（ＥＰＡ、ＤＨＡ、ＤＰＡ） |
| EP2861227A4 (en) * | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
-
2013
- 2013-12-06 EP EP13861305.4A patent/EP2928462A4/en not_active Withdrawn
- 2013-12-06 KR KR1020157016331A patent/KR20150103671A/ko not_active Ceased
- 2013-12-06 JP JP2015545896A patent/JP2016501249A/ja active Pending
- 2013-12-06 WO PCT/US2013/073701 patent/WO2014089501A1/en not_active Ceased
- 2013-12-06 EP EP13861394.8A patent/EP2929041A4/en not_active Withdrawn
- 2013-12-06 MX MX2015007085A patent/MX2015007085A/es unknown
- 2013-12-06 WO PCT/US2013/073714 patent/WO2014089511A2/en not_active Ceased
- 2013-12-06 CN CN202010984870.2A patent/CN112107570A/zh active Pending
- 2013-12-06 KR KR1020157017202A patent/KR20150103009A/ko not_active Ceased
- 2013-12-06 KR KR1020217013255A patent/KR20210059779A/ko not_active Abandoned
- 2013-12-06 MX MX2015007082A patent/MX2015007082A/es unknown
- 2013-12-06 AU AU2013354979A patent/AU2013354979A1/en not_active Abandoned
- 2013-12-06 JP JP2015545894A patent/JP6881893B2/ja not_active Expired - Fee Related
- 2013-12-06 CN CN202110585483.6A patent/CN113274378A/zh active Pending
- 2013-12-06 EP EP21170003.4A patent/EP3888646A1/en not_active Withdrawn
- 2013-12-06 AU AU2013354969A patent/AU2013354969A1/en not_active Abandoned
- 2013-12-06 CN CN201380063980.3A patent/CN104937103A/zh active Pending
- 2013-12-06 CA CA2894366A patent/CA2894366A1/en not_active Abandoned
- 2013-12-06 CA CA2894183A patent/CA2894183A1/en not_active Abandoned
- 2013-12-06 CN CN201380064003.5A patent/CN104902888A/zh active Pending
-
2015
- 2015-06-10 IN IN5009DE2015 patent/IN2015DE05009A/xx unknown
- 2015-06-10 IN IN1505MU2015 patent/IN2015MU01505A/xx unknown
-
2017
- 2017-09-22 AU AU2017232203A patent/AU2017232203A1/en not_active Abandoned
-
2018
- 2018-09-12 AU AU2018229440A patent/AU2018229440A1/en not_active Abandoned
-
2019
- 2019-06-20 JP JP2019114492A patent/JP2019172697A/ja active Pending
- 2019-08-14 AU AU2019216634A patent/AU2019216634A1/en not_active Abandoned
-
2020
- 2020-06-03 AU AU2020203658A patent/AU2020203658A1/en not_active Abandoned
-
2021
- 2021-03-24 AU AU2021201865A patent/AU2021201865A1/en not_active Abandoned
- 2021-05-19 JP JP2021084578A patent/JP2021120407A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501249A5 (enExample) | ||
| NZ626699A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| MX356427B (es) | Emulsion que contiene hormona. | |
| HRP20200065T1 (hr) | Upotreba etilnog estera ikozapentaenske kiseline u liječenju hipertrigliceridemije | |
| JP2015143248A5 (enExample) | ||
| NZ734905A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| JP2016512245A5 (ja) | マイボーム腺を標的とする組成物 | |
| RU2019137026A (ru) | Сложные эфиры для лечения офтальмологических воспалительных заболеваний | |
| PH12015500930A1 (en) | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | |
| PH12016500100A1 (en) | Self-emulsifying composition of omega3 fatty acid | |
| IN2014DN08449A (enExample) | ||
| NZ737380A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| JP2014510166A5 (enExample) | ||
| WO2008036353A3 (en) | Omega-3 diglyceride emulsions | |
| MX384954B (es) | Composición auto-emulsionante de ácido graso ?3. | |
| WO2009091538A3 (en) | Pharmaceutical composition comprising epa and dha for treating hypertriglyceridemia and hypercholesterolemia | |
| JP2016501248A5 (enExample) | ||
| CL2012001124A1 (es) | Composición farmacéutica que comprende un extracto terapéutico concentrado, que comprende fosfolípidos en concentración de 60 a 99% y uso para tratar enfermedades cardiovasculares, reducir niveles de triglicérido, reducir colesterol ldl y aumentar colesterol hdl. | |
| HK1198515A1 (en) | Fatty acid compositions | |
| JP2016511753A5 (enExample) | ||
| BR112018001164A2 (pt) | composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular | |
| RU2016129079A (ru) | Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы | |
| WO2014089511A3 (en) | Administering compositions comprising docosapentaenoic acid | |
| WO2011137160A3 (en) | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans | |
| WO2006111633A3 (fr) | Utilisation de la lecithine comme medicament dans le traitement du psoriasis |